Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016

(BUSINESS WIRE)-- Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinical trial has been selected by the American Association for the Study of Liver Disease (AASLD) for presentation during the late-breaking oral abstract session at its annual meeting to be held November 11-15, 2016 in Boston, U.S.A.

The REP 401 protocol http://me-newswire.net//news/18796/en...